IBRX Q3 2020 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena

IBRXImmunityBio, Inc.

$8B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$151,000+1158.3% YoY

Gross Profit

$151,000100.0% margin

Operating Income

-$66M-43627.2% margin

Net Income

-$66M-43445.7% margin

EPS (Diluted)

$-0.17

QoQ Revenue Growth

-65.4%

Cash Flow

Operating Cash Flow

-$37M

Free Cash Flow

-$39M

Stock-Based Comp.

$714,000

Balance Sheet

Total Assets

$117M

Total Liabilities

$314M

Stockholders' Equity

-$200M

Cash & Equivalents

$57M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$151,000	$12,000	+1158.3%
Gross Profit	$151,000	$12,000	+1158.3%
Operating Income	-$66M	-$16M	-322.9%
Net Income	-$66M	-$16M	-320.9%